Cathepsin G peptide–human leukocyte antigen complex

The **cathepsin G peptide–human leukocyte antigen complex** refers to a cell-surface molecular complex formed by the presentation of a peptide derived from cathepsin G (CG), a neutrophil serine protease, in the context of human leukocyte antigen (HLA, especially class I molecules such as HLA-A*0201). This complex is recognized by cytotoxic T lymphocytes, enabling immune targeting of cells that abnormally process or express cathepsin G, such as acute myeloid leukemia (AML) blasts. Recent therapeutic strategies have focused on this complex as a highly specific tumor-associated antigen for immunotherapy, utilizing T cell receptor-mimic antibodies and engineered T cells to selectively target leukemic cells while sparing normal tissues. The complex plays a critical role in adaptive immunity, serving as both an immune target and a potential biomarker for disease and therapeutic selection; its exploitation must be balanced against potential immunopathology and off-target effects[1][2][3][4].

Other names

CatG peptide–HLA complexCathepsin G–MHC complexCG1/HLA-A2 complexCathepsin G epitope–MHC complex

Recognition by cytotoxic T cells leading to targeted cell lysis[2][4] Redirection of T cells to target the complex via bispecific antibodies[4] Immune-mediated cytotoxicity